In this study, we focused on the development of dual inhibitors of histone deacetylases (HDACs) and cyclooxygenase-2 (COX-2), both of which are known to be overexpressed in several cancer types [7,12,13,14,15,16]. Here, PTGS2 is linked to cancer.